{
    "clinical_study": {
        "@rank": "48576", 
        "arm_group": [
            {
                "arm_group_label": "PAD Followed by ASCT", 
                "arm_group_type": "Experimental", 
                "description": "Drug: Bortezomib(1.3mg/m2, iv, on day 1, 4, 8, 11)\nDrug: Epidoxorubicin(15 mg/m2, iv, on days 1-4)\nDrug: Dexamethasone(40mg, orally, on days 1-4)\nAfter received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.\nNot suitable for transplant patients will continue accept treatment for 8 cycles."
            }, 
            {
                "arm_group_label": "VCD Followed by ASCT", 
                "arm_group_type": "Experimental", 
                "description": "Drug: Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11)\nDrug: Cyclophosphamide (200mg/m2, orally, on days 1-5)\nDrug: Dexamethasone(40mg, orally, on days 1-4)\nAfter received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.\nNot suitable for transplant patients will continue accept treatment for 8 cycles."
            }
        ], 
        "brief_summary": {
            "textblock": "A multicenter, double arms, prospective randomized controlled phase 4 study. Approximately\n      50 previously untreated subjects with multiple myeloma will be enrolled. The study will\n      consist of 6 phases, screening, treatment and follow-up."
        }, 
        "brief_title": "A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Screening\n\n      At the screening visit, informed consent will be obtained from all subjects who are deemed\n      potentially eligible for enrollment in the study, according to the protocol-specified\n      inclusion and exclusion criteria.\n\n      Treatment\n\n      Eligible patients are randomly assigned to receive either treatment PAD or VCD. All eligible\n      subjects will be evaluated after 4 cycles treatment. According to the assessment of\n      researchers and the willingness of patients to decide whether to autologous stem-cell\n      transplantation (ASCT). Suitable for transplant patients will accept hematopoietic stem cell\n      transplantation. Not suitable for transplant patients will continue accept treatment for 8\n      cycles. The patients who accept more than 4 cycles treatment will receive efficacy\n      evaluation.\n\n      Follow-up\n\n      All patients will receive 12 months of follow-up after the treatment period. Follow-up at 4,\n      6, 8 and 12 month after the treatment period respectively. Subjects who have disease\n      progression or accept other resistance myeloma therapy during the 12 months of follow-up\n      phase will stop assessed about the study and start followed up only for survival status\n      every 6 months through telephone interviews or to research center follow-up. All patients\n      will accept the follow-up for survival until last case patient who complete follow-up.\n\n      Safety will be evaluated throughout the study by assessment of adverse events (AEs),\n      physical examination, vital signs and clinical laboratory findings."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men or women aged <65 years.\n\n          2. Previously untreated subjects with multiple myeloma.\n\n          3. No clinically significant cardiac amyloidosis (Echocardiography septal\u226410mm, brain\n             natriuretic peptide (BNP) < 500).\n\n          4. Pulmonary infection (if any) must be controlled effectively.\n\n          5. Chronic viral hepatitis (if any) must be controlled effectively.(Subjects with HBs Ag\n             positive need to monitor hepatitis B virus-DNA (HBV-DNA )quantitative test\n             regularly\uff09\uff1b\n\n          6. Liver function (aminotransferase, bilirubin\uff09?2 x the upper limit of normal (ULN).\n\n          7. Expected lifetime More than 3 months.\n\n          8. Be able to read and sign (or their legally-acceptable representatives must sign) an\n             informed consent document indicating that they understand the purpose of and\n             procedures required for the study and are willing to participate in the study.\n\n        Exclusion Criteria:\n\n          1. Patients with relapsed multiple myeloma.\n\n          2. Need to change the program according to the researchers' evaluated patients with\n             disease progression during treatment.\n\n          3. Had uncontrolled or severe cardiovascular disease. Had a myocardial infarction within\n             6 months of enrolment, New York Heart Association (NYHA) Class III or IV heart\n             failure, uncontrolled angina, clinically significant pericardial disease, or cardiac\n             amyloidosis.\n\n          4. Has a history of allergic reaction to compounds containing boron or mannitol.\n\n          5. Severe neuropathy may affect the treatment, according to the researchers to\n             determine.\n\n          6. According to the program or the investigator's judgment, the patient is suffering\n             from a serious physical illness or mental illness may interfere with participation in\n             this clinical study.\n\n          7. Concurrent treatment with another investigational agent.\n\n          8. Pregnant or breast-feeding women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01868828", 
            "org_study_id": "PAD VS VCD Clinical Protocol"
        }, 
        "intervention": [
            {
                "arm_group_label": "PAD Followed by ASCT", 
                "description": "Induction Therapy of PAD for 4 cycles.", 
                "intervention_name": "PAD", 
                "intervention_type": "Drug", 
                "other_name": "Induction Therapy"
            }, 
            {
                "arm_group_label": "VCD Followed by ASCT", 
                "description": "Induction Therapy of VCD for 4 cycles.", 
                "intervention_name": "VCD", 
                "intervention_type": "Drug", 
                "other_name": "Induction Therapy"
            }, 
            {
                "arm_group_label": [
                    "PAD Followed by ASCT", 
                    "VCD Followed by ASCT"
                ], 
                "description": "Not suitable for transplant patients will continue accept treatment for 8 cycles.", 
                "intervention_name": "ASCT", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Dexamethasone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple Myeloma", 
            "Combination Therapy"
        ], 
        "lastchanged_date": "June 4, 2013", 
        "location": {
            "contact": {
                "email": "onco_velcade123@163.com", 
                "last_name": "Jin Lu, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100044"
                }, 
                "name": "Peking University People's Hospital, Institute of Hematology, Peking University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma.", 
        "overall_contact": {
            "email": "onco_velcade123@163.com", 
            "last_name": "Jin Lu, PhD"
        }, 
        "overall_official": {
            "affiliation": "Peking University People's Hospital", 
            "last_name": "Jin Lu, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Complete Response Rate", 
            "safety_issue": "No", 
            "time_frame": "Up to cycle 4 (with 28 days per cycle)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01868828"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University People's Hospital", 
            "investigator_full_name": "Jin Lu", 
            "investigator_title": "Associate Chief Physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety evaluations will be based on scheduled clinical laboratory tests, electrocardiogram or cardiac ultrasonography (when appropriate), vital signs, physical examination and number of adverse events.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline, on day 1 of each cycle, and after 4, 6, 12 and 18 months of follow-up."
            }, 
            {
                "description": "Overall response rate included Complete Response (CR), Very good partial response (VGPR) and PR, before the new treatment, two consecutive evaluations are in line with defined criteria in order to confirm the efficacy evaluation.", 
                "measure": "Overall Response Rate", 
                "safety_issue": "No", 
                "time_frame": "At baseline, on day 28 of each cycle for 4 cycles."
            }, 
            {
                "measure": "Time To Response", 
                "safety_issue": "No", 
                "time_frame": "At baseline, on day 28 of each cycle for 4 cycles."
            }, 
            {
                "measure": "1-year Survival Rate", 
                "safety_issue": "No", 
                "time_frame": "At baseline, on day 28 of each cycle, and after 4, 6, 12 and 18 months of follow-up."
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "At baseline, on day 28 of each cycle, and after 4, 6, 12 and 18 months of follow-up."
            }
        ], 
        "source": "Peking University People's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University People's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}